Treating Patients With Traumatic Chondral Lesions With Autologous Bone Marrow Cells Derived Engineered Tissues - Engineered Osteochondral Tissue

Exclusion Criteria30

• Disease Factor---
• Previous cartilage repair surgery (OATS or ACI/MACI) in the index knee
• Previous injectional treatments such as HA/PRP/stem cell in the index knee within 3 months before informed consent
• Presence of a clinically relevant patellofemoral cartilage lesion in the index knee (patella/trochlea/both)
• Inflammatory joint disease (specific or non-specific arthritis)
• Metabolic diseases (gout or rheumatism)
• Advanced Osteoarthritis (Radiologically apparent degenerative joint disease in the target knee as determined by Kellgren \& Lawrence Grade \>2)
• Osteochondritis dissecans
• Multiple or uncontained lesions as detected by MRI or arthroscopy
• Uncorrected ligament deficiency
• Uncorrected varus or valgus malalignment exceeding 5°
• Ongoing Infection or skin diseases at target knee joint
• Significant meniscal loss
• Patient Factor---
• Subjects who are not able or not willing to give voluntary, written informed consent to participate in this study
• Skeletal immaturity
• Female subjects who are pregnant or lactating
• Body mass index \> 30 kg/m2
• Malignancy
• Steroid therapy by systemic or intra-articular route within the last 60 days before informed consent or intramuscular or oral steroids within the last 30 days before informed consent
• Contraindications to MR imaging
• Drug addiction (including narcotic, anesthetic or alcohol addiction)
• Patients who are at higher risk for post-surgical bleeding (e.g., bleeding disorder; taking anticoagulants except low dose aspirin
• Patients who are at higher risk for post-surgical infection (e.g., taking immunosuppressants; have a severe infection or a history of serious infection)
• Known allergy to porcine/bovine collagen
• Any concomitant painful or disabling disease of the spine, hips, or lower limbs that would interfere with evaluation of the afflicted knee
• Patients with human immunodeficiency virus, hepatitis, or syphilis
• Any clinically significant or symptomatic vascular or neurologic disorder of the lower extremities
• Poor general health condition as judged by investigator
• Unable to do follow up